Saranas Early Bird Bleed Monitoring System

The Saranas Early Bird Bleed Monitoring System provides a conduit for femoral vascular access and employs bioimpedance technology to detect extravascular fluid accumulation, offering early indication of potential internal bleeding. This version enhances detection accuracy for various bleed rates through an updated algorithm incorporating both impedance drop thresholds and rate-of-change analysis, alongside a new system reset functionality.

The Saranas Early Bird Bleed Monitoring System is a single-use, sterile medical device designed to facilitate the introduction of catheters and other interventional devices into the femoral artery or vein while maintaining hemostasis during endovascular procedures. Its primary function is to provide physicians with an early warning of potential internal bleeding complications by detecting and monitoring the accumulation of extravascular fluid. The system comprises an introducer sheath with four embedded electrodes, a user interface display (UID), and a compatible dilator. The electrodes connect to a battery-powered impedance analyzer within the UID, which monitors changes in bioimpedance in the tissue surrounding the insertion site. This iteration of the Early Bird system features significant firmware enhancements aimed at improving bleed detection capabilities, particularly for slower bleeds. The detection algorithm has been augmented to include an impedance drop threshold from a baseline value, supplementing the existing slope-based bioimpedance drop rate detection. A Level 1 bleed alert is now triggered by either of these criteria. Additionally, the firmware update includes an improved power-on self-test to reduce false error indications and introduces a user-activated reset function. This reset allows clinicians to re-establish the bioimpedance baseline and restart monitoring, which is particularly useful if the device is dislodged or if bleeding is already active at insertion. The device's physical characteristics, materials, dimensions, and shelf life (now 2 years) remain consistent with the predicate, ensuring no new biocompatibility or mechanical concerns.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the enhanced algorithm's sensitivity and specificity for detecting slow bleeds, using the new impedance drop threshold, compare to the predicate device's slope-based detection in real-world clinical scenarios?; What is the clinical impact of the new reset functionality on managing cases where initial baseline bioimpedance might be skewed or when a re-assessment is needed post-intervention?; Are there quantifiable data on the reduction of false error indications due to the widened upper limit of the calibration self-check during the improved power-on self-test?; Beyond detecting extravascular fluid accumulation, can the bioimpedance data provide any quantitative estimation of the bleed volume or rate?; What specific types of internal bleeding complications (e.g., hematoma, retroperitoneal bleed) is the enhanced algorithm now more adept at detecting compared to the previous version?